<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03527238</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201800053 -N -A</org_study_id>
    <secondary_id>1R21DK116140-01</secondary_id>
    <nct_id>NCT03527238</nct_id>
  </id_info>
  <brief_title>Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine</brief_title>
  <acronym>PPM - Pro</acronym>
  <official_title>Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial applying Phenotypic Precision Medicine (PPM) to tacrolimus dosing in liver&#xD;
      and/or kidney transplant recipients to show improvement in maintaining drug trough levels&#xD;
      within the target range.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The introduction of calcineurin inhibitors like tacrolimus has greatly reduced the incidence&#xD;
      of acute rejection, improving graft and patient survival after transplantation. However,&#xD;
      tacrolimus, one of the most widely used immunosuppressants and a mainstay of solid organ&#xD;
      transplantation, has a narrow therapeutic index and wide pharmacokinetic variability. As&#xD;
      such, there is a clear need for precision medicine to address post-transplant&#xD;
      immunosuppression.&#xD;
&#xD;
      The study team has developed a powerful platform [Phenotypic Precision Medicine (PPM)] that&#xD;
      utilizes patient-specific clinical data which represents each patient's response to drug&#xD;
      treatment. This platform can efficiently prescribe precise and optimized drug doses despite&#xD;
      the frequent changes to patient treatment regimens following transplantation. This&#xD;
      potentially can have a profound effect on drug metabolism.&#xD;
&#xD;
      The aim of this project is to use PPM to uncover valuable and previously unknown information&#xD;
      pertaining to patient dose requirements and correlate them with patient clinical and other&#xD;
      contextual information. This study is also expected to reveal vital patient subpopulation&#xD;
      information; and any future discovery of quantitative biomarkers as measures of&#xD;
      immunosuppression will serve as a gateway towards even more effective personalized and&#xD;
      relevant drug dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 21, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Actual">June 2, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tacrolimus Target Trough Level Maintenance</measure>
    <time_frame>2 weeks</time_frame>
    <description>Days within Tacrolimus Target Trough Level</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Liver Transplant</condition>
  <condition>Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care Tacrolimus Drug Dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenotypic Precision Medicine (PPM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PPM-based Computation Assisted Drug Dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PPM-based Computation Assisted Drug Dosing</intervention_name>
    <description>Tacrolimus dosing based on application of PPM.</description>
    <arm_group_label>Phenotypic Precision Medicine (PPM)</arm_group_label>
    <other_name>Computation based dosing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Dosing of calcineurin inhibitor, tacrolimus</description>
    <arm_group_label>Phenotypic Precision Medicine (PPM)</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adults undergoing liver and/or kidney transplantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  transplant patients with contraindications to tacrolimus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Zarrinpar, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health at the University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University of Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>119077</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 4, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2018</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phenotypic Precision Medicine (PPM)</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Calcineurin Inhibitors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 12, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

